logo

For the Inventor, By the Inventor

Gothenburg, Sweden

Bjorn Rydevik

This inventor holds 5 USPTO granted patents and 2 published patent applications. Top assignee: Sciaticon Ab. Active years: 2010-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bjorn Rydevik. Retrieved from https://idiyas.com/inventor/bjorn-rydevik

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 5 

Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Location History:

  • Göthenburg, SE (2010)
  • Gothenburg, SE (2010)
  • Göteborg, SE (2011)

Company Filing History:

goldMedal5 out of 6 
 
Sciaticon Ab
 patents

Years Active: 2010-2011

Loading Chart...
5 patents (USPTO):Explore Patents
1. 8057792 - Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus (2011-11-15),
2. 7906481 - Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus (2011-03-15),
3. 7811990 - Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus (2010-10-12),
4. 7723357 - Thalidomide and thalidomide derivatives for treating spinal disorders mediated by nucleus pulposus (2010-05-25),
5. 7708995 - Use of TNF-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus (2010-05-04),

Title: The Innovative Contributions of Bjorn Rydevik

Introduction

Bjorn Rydevik is a notable inventor based in Göteborg, Sweden. He has made significant contributions to the field of medical science, particularly in the treatment of nerve disorders. With a total of 5 patents to his name, Rydevik's work has the potential to impact many lives.

Latest Patents

Among his latest patents is a method involving the use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus. This invention relates to a pharmaceutical composition for the treatment of nerve disorders, which includes the administration of a therapeutically effective dosage of various inhibitors. Specifically, it emphasizes the use of TNF inhibitors, among others, to address these medical conditions. Another significant patent focuses on the use of TNF-alpha inhibitors for treating spinal disorders mediated by nucleus pulposus. This method aims to treat nerve disorders in mammals or vertebrates by administering a TNF-alpha inhibitor, which can be crucial for nerve root injury and other related issues.

Career Highlights

Bjorn Rydevik is currently associated with Sciaticon AB, where he continues to innovate and develop new solutions for nerve-related disorders. His expertise and dedication to research have positioned him as a key figure in his field.

Collaborations

Rydevik collaborates with Kjell Olmarker, a fellow professional in the medical research community. Their partnership enhances the potential for groundbreaking advancements in their shared area of expertise.

Conclusion

Bjorn Rydevik's contributions to the field of medical science through his innovative patents demonstrate his commitment to improving treatments for nerve disorders. His work at Sciaticon AB and collaborations with other professionals highlight the importance of teamwork in advancing medical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…